Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01170286 · ClinicalTrials.gov registry record · Phase 1
Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy
A Phase 1 study, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT01170286: Completed Phase 1 study, sponsored by DBV Technologies.
NCT01170286 is a Phase 1 study that has completed, run by DBV Technologies. The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01170286, a Phase 1 study, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this phase 1b study is to evaluate the safety and tolerability of repeated epicutaneous applications of peanut proteins using a patch delivery system (Viaskin device) in peanut allergic subjects.
Primary Outcome
The primary outcome measure is safety and the subjects will undergo the following procedures: physical examination including patch application site examination for evaluation of any skin reaction, vital signs, blood and urine collection for blood and urine analysis, ECG, Peak Expiratory Flow and spirometry (FEV1). Adverse events, treatment-emergent adverse events, and serious adverse events will be classified according to severity, treatment relatedness, the system/organ class affected, and the
Interventions
- BIOLOGICAL Whole peanut extract
- BIOLOGICAL Placebo formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
What the finished NCT01170286 record still lists
NCT01170286 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).
The record links to 0 conditions, and to 2 interventions - of which Whole peanut extract is the first listed.
NCT01170286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01170286 about?
NCT01170286 is a clinical study titled "Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy". The purpose of this phase 1b study is to evaluate the safety and tolerability of repeated epicutaneous applications of peanut proteins using a patch delivery system (Viaskin device) in peanut allergic subjects.
What is the current status of trial NCT01170286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2010-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01170286?
The interventions under investigation include: Whole peanut extract (BIOLOGICAL), Placebo formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT01170286?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01170286's enrollment target sits among peer trials
100 546th of 2000 higher than 1,411 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia